Stockscreener 앱 받기
36.84
1.37%
-0.515
전일 마감가:
$37.35
열려 있는:
$37.35
하루 거래량:
1.41M
Relative Volume:
0.70
시가총액:
$4.91B
수익:
$18.47M
순이익/손실:
$-589.53M
주가수익비율:
-7.0029
EPS:
-5.26
순현금흐름:
$-399.80M
1주 성능:
-10.63%
1개월 성능:
-1.39%
6개월 성능:
-29.86%
1년 성능:
-43.56%
1일 변동 폭
$35.58
$37.40
1주일 범위
$34.88
$43.51
52주 변동 폭
$32.74
$68.44
Cytokinetics Inc Stock (CYTK) Company Profile
명칭
Cytokinetics Inc
전화
(650) 624-3000
주소
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
CYTK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
36.83 | 4.91B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.64 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.76 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.67 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.45 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.43 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-24 | 개시 | Barclays | Overweight |
| 2025-02-07 | 개시 | Citigroup | Buy |
| 2025-01-22 | 개시 | Stifel | Buy |
| 2024-11-08 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-07 | 개시 | B. Riley Securities | Buy |
| 2023-08-15 | 개시 | SVB Securities | Outperform |
| 2023-02-17 | 개시 | BofA Securities | Neutral |
| 2022-12-23 | 재확인 | Needham | Buy |
| 2022-12-20 | 개시 | Truist | Buy |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-01-28 | 개시 | Goldman | Buy |
| 2021-12-22 | 개시 | Oppenheimer | Outperform |
| 2021-12-10 | 개시 | JP Morgan | Overweight |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2021-02-18 | 개시 | Barclays | Overweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-29 | 개시 | Goldman | Neutral |
| 2020-07-10 | 개시 | Raymond James | Strong Buy |
| 2020-05-05 | 개시 | Mizuho | Buy |
| 2020-04-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 재개 | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 재확인 | Morgan Stanley | Overweight |
| 2017-11-22 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2017-11-21 | 재확인 | H.C. Wainwright | Buy |
| 2017-07-31 | 개시 | Morgan Stanley | Overweight |
| 2017-03-08 | 개시 | Rodman & Renshaw | Buy |
| 2017-02-06 | 업그레이드 | Needham | Buy → Strong Buy |
| 2016-12-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 재확인 | Needham | Buy |
| 2015-11-10 | 재확인 | FBR Capital | Outperform |
| 2015-11-09 | 재확인 | ROTH Capital | Buy |
| 2015-07-24 | 재확인 | MLV & Co | Buy |
| 2014-12-31 | 재확인 | ROTH Capital | Buy |
| 2014-11-04 | 업그레이드 | MLV & Co | Hold → Buy |
| 2014-04-28 | 재확인 | Needham | Buy |
모두보기
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
Cytokinetics Inc (CYTK) Q1 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
Why Cytokinetics, Inc. (CYTK) Went Down On Friday - Insider Monkey
10 Firms Battered by Poor Earnings, Dismal Outlook - Insider Monkey
Cytokinetics (CYTK) Target Price Lowered by UBS Analyst | CYTK S - GuruFocus
JMP reiterates $78 target on Cytokinetics stock, sees potential By Investing.com - Investing.com South Africa
CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm - Business Wire
FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months - Benzinga
JMP reiterates $78 target on Cytokinetics stock, sees potential - Investing.com Australia
FDA Pushes Out Decision for Cytokinetics Heart Drug to Review Proposed Safety Plan - MedCity News
Cytokinetics (CYTK) Faces FDA Delay for Aficamten Approval - GuruFocus
Cytokinetics, Incorporated Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your RightsCYTK - Business Wire
Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma - BioPharma Dive
Oh them REMS: Cytokinetics heart-hit with FDA delay - BioWorld MedTech
UBS Adjusts Price Target for Cytokinetics (CYTK) Amid Ongoing Challenges | CYTK Stock News - GuruFocus
Cytokinetics (CYTK): Needham Reiterates Buy Rating with $72 Targ - GuruFocus
UBS Adjusts Price Target on Cytokinetics to $41 From $47, Maintains Neutral Rating - marketscreener.com
Cytokinetics (CYTK) Faces Stock Drop After FDA Extends Drug Revi - GuruFocus
Cytokinetics stock falls on FDA delay for heart drug By Investing.com - Investing.com Canada
Cytokinetics stock drops on regulatory update (CYTK:NASDAQ) - Seeking Alpha
FDA Extends Review Period for Cytokinetics' (CYTK) Aficamten App - GuruFocus
FDA delays decision for Cytokinetics heart-failure drug - The Business Journals
FDA extends review period for Cytokinetics’ heart drug By Investing.com - Investing.com Canada
Cytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy - The Manila Times
Cytokinetics Announces FDA Extension for Aficamten NDA Action Date to December 26, 2025 - Nasdaq
Barclays Initiates Coverage of Cytokinetics (BIT:1CYTK) with Overweight Recommendation - Nasdaq
Cytokinetics to Participate in May Investor Conferences - The Manila Times
Cytokinetics Leadership to Present at Citizens Life Sciences and RBC Healthcare Conferences - Stock Titan
Barclays Initiates Coverage of Cytokinetics (CYTK) with Overweight Recommendation - MSN
Cytokinetics gains as Barclays initiates bullish view on lead drug’s approval - MSN
Cytokinetics stock up on Barclays bullish view (CYTK:NASDAQ) - Seeking Alpha
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday - Benzinga
Cytokinetics (CYTK) Receives Overweight Rating as FDA Decision Nears | CYTK Stock News - GuruFocus
Barclays sets Cytokinetics stock overweight with $55 target By Investing.com - Investing.com Canada
Cytokinetics to Announce First Quarter Results on May 6, 2025 - The Manila Times
Cytokinetics Sets Q1 2025 Earnings Date: Key Biotech Financial Results Coming May 6 - Stock Titan
H.C. Wainwright maintains Buy on Cytokinetics stock, $120 target By Investing.com - Investing.com Canada
H.C. Wainwright maintains Buy on Cytokinetics stock, $120 target - Investing.com India
Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach - Benzinga
H.C. Wainwright maintains $120 target on Cytokinetics stock By Investing.com - Investing.com Canada
Bristol Myers' Camzyos Update Boosts Prospects for Cytokinetics (CYTK) | BMY Stock News - GuruFocus
Stifel maintains Cytokinetics stock buy rating, $87 target By Investing.com - Investing.com India
Stifel maintains Cytokinetics stock buy rating, $87 target - Investing.com
US FDA Expands Label For BMS’s Camzyos Days After Phase III Stumble - insights.citeline.com
Is Cytokinetics Inc. (NASDAQ:CYTK) the Best High Short Interest Stock to Buy Now? - Yahoo
10 Best High Short Interest Stocks to Buy Now - Insider Monkey
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cytokinetics director John Henderson sells $123,325 in stock By Investing.com - Investing.com South Africa
Cytokinetics director John Henderson sells $123,325 in stock - Investing.com Australia
Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It - MSN
Cytokinetics (CYTK) Gains Favor as Key Trial by Bristol-Myers Fa - GuruFocus
Camzyos nHCM Failure Could Open Door To Threat From Cytokinetics’ Aficamten - insights.citeline.com
Cytokinetics Inc (CYTK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cytokinetics Inc 주식 (CYTK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Apr 22 '25 |
Option Exercise |
10.60 |
2,000 |
21,200 |
142,255 |
| Malik Fady Ibraham | EVP Research & Development |
Apr 22 '25 |
Sale |
38.11 |
2,000 |
76,220 |
140,255 |
| WIERENGA WENDALL | Director |
Apr 21 '25 |
Option Exercise |
6.21 |
20,000 |
124,200 |
44,848 |
| WIERENGA WENDALL | Director |
Apr 21 '25 |
Sale |
38.46 |
20,000 |
769,200 |
24,848 |
0.28%
0.47%
자본화:
|
볼륨(24시간):